Tiny pills, big impacts: A systematic review on the endocrine disrupting effects of paediatric pharmaceuticals

被引:0
作者
Tourvieilhe, L. [1 ]
Salvo, F. [2 ,3 ]
Breant, V. [4 ]
Kassai, B. [1 ,5 ]
Portefaix, A. [1 ,5 ]
机构
[1] Hosp Civils Lyon, INSERM, Clin Invest Ctr, CIC 1407, Bron, France
[2] Univ Bordeaux, INSERM, BPH, Team AHeaD,U1219, Bordeaux, France
[3] Bordeaux Univ Hosp, Dept Med Pharmacol, Publ Hlth Unit, Bordeaux, France
[4] Hosp Civils Lyon, Groupement Hosp Est, Pharm Dept, Bron, France
[5] Univ Lyon 1 Claude Bernard, CNRS, UMR 5558, Lab Biometrie & Biol Evolut, Villeurbanne, France
关键词
Endocrine disorders; Medication; Parabens; Essential oils; Environmental health; Pediatrics; WEIGHT-GAIN; PUBERTAL MATURATION; EPILEPTIC GIRLS; SERENOA-REPENS; URINARY LEVELS; YOUNG-WOMEN; VALPROATE; CHILDREN; CHEMICALS; LAVENDER;
D O I
10.1016/j.etap.2024.104549
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Endocrine disrupting chemicals (EDCs) may impact children's health, with medicines as a possible exposure source. Objective: to assess the potential impact of substances in paediatric medications and essential oils on children as EDC. It is a systematic review of five databases including Medline following the PECOT approach. The review focused on publications about children exposed to medication (active ingredients or excipients of interest) and having developed clinical signs of endocrine dysfunction. Out of 946 studies identified, 28 studies were included. They revealed that parabens, lavender essential oils and anti-epileptics are the most identified pharmaceutical products. The reported outcomes relate to puberty, thyroid disorders, obesity and growth. The evidence indicates potential risks, but the overall quality of available data is limited. This systematic review exposes a lack of robust evidence linking paediatric medication exposure to EDC, predominantly relying on case reports. It cautions about potential conflicts of interest.
引用
收藏
页数:9
相关论文
共 81 条
  • [1] [Anonymous], REGULATION EC 1907 2
  • [2] [Anonymous], 2021, Prescrire Int, V30, P96
  • [3] [Anonymous], Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006
  • [4] Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial
    Biton, V
    Levisohn, P
    Hoyler, S
    Vuong, A
    Hammer, AE
    [J]. JOURNAL OF CHILD NEUROLOGY, 2003, 18 (02) : 133 - 139
  • [5] Possible endocrine disrupting effects of parabens and their metabolites
    Boberg, Julie
    Taxvig, Camilla
    Christiansen, Sofie
    Hass, Ulla
    [J]. REPRODUCTIVE TOXICOLOGY, 2010, 30 (02) : 301 - 312
  • [6] Early-life exposure to EDCs: role in childhood obesity and neurodevelopment
    Braun, Joseph M.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (03) : 161 - 173
  • [7] Lack of evidence that essential oils affect puberty
    Carson, Christine F.
    Tisserand, Robert
    Larkman, Tony
    [J]. REPRODUCTIVE TOXICOLOGY, 2014, 44 : 50 - 51
  • [8] Diagnosis and management of precocious sexual maturation: an updated review
    Cheuiche, Amanda Veiga
    da Silveira, Leticia Guimaraes
    Pedroso de Paula, Leila Cristina
    Siqueira Lucena, Iara Regina
    Silveiro, Sandra Pinho
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2021, 180 (10) : 3073 - 3087
  • [9] Triclosan: environmental exposure, toxicity and mechanisms of action
    Dann, Andrea B.
    Hontela, Alice
    [J]. JOURNAL OF APPLIED TOXICOLOGY, 2011, 31 (04) : 285 - 311
  • [10] Endocrine effects of valproate in adolescent girls with epilepsy
    de Vries, Liat
    Karasik, Anna
    Landau, Zohar
    Phillip, Moshe
    Kiviti, Sara
    Goldberg-Stern, Hadassa
    [J]. EPILEPSIA, 2007, 48 (03) : 470 - 477